All News
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
Read Article
What is Colchicine Worth? (6.23.2023)
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
Read Article
Diagnostic Yield of Cranial and Large Vessel Imaging in GCA
Combined cranial and large vessel ultrasound and PET/CT provided excellent accuracy for the diagnosis of giant cell arteritis (GCA).
Read Article
EULAR 2023 recommendation for imaging in large vessel vasculitis
Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease. At EULAR 2023, recommendations for imaging modalities for large vessel vasculitis were discussed. These were evidence-based recommendations adapted for practicality in clinical use.
Read Article
New treatment for Takayasu’s arteritis?
Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.
Read Article
ANCA-associated vasculitis: beyond therapy with rituximab?
Following the success of Phase 3 randomised controlled trials of non-renal and renal vasculitis, therapy with rituximab has tremendously improved the outcomes of AAV patients. However, some patients are unable to taper their glucocorticoids during rituximab therapy while others appear to be refractory to therapy, particularly those with EGPA. Hence, what are other current or future approaches beyond rituximab?
Read Article
Links:
Links:
Links:
Links:
Links:
